Tavistock Life Sciences
VC Fund
Windermere, United States
Tavistock Life Sciences is a VC fund in Windermere focused on Biotechnology and Health Care. Tavistock Group is an international private investment organization comprised of a family office, trading operation, and a portfolio of public investments and private companies. These investments are concentrated in nine primary sectors, including: real estate, hospitality, restaurants, sports, energy, retail, biotechnology and life sciences,agriculture, and finance.
- Total investments:
- 23
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Tavistock Life Sciences invests in
Stages Tavistock Life Sciences invests in
Countries Tavistock Life Sciences invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Series B
- $5M–$32M
- Series C
- $47M–$400M
- Post-IPO Equity
- $6M–$502M
Investment Focus
Industry
- Biotechnology 15 (65%)
- Health Care 11 (48%)
- Therapeutics 6 (26%)
- Medical 5 (22%)
- Biopharma 4 (17%)
Stage
- Series C 7 (30%)
- Series B 5 (22%)
- Post-IPO Equity 4 (17%)
- Pre-Seed 2 (9%)
- Series A 1 (4%)
Country
- United States 14 (61%)
- Canada 2 (9%)
- Australia 1 (4%)
- United Kingdom 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Christopher Fuglesang
Team Member
|
Team Member | Total investments: 9 | Find email | |
Joe Lewis
Founder & Chairman
|
Founder & Chairman | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Kinotek
|
Kinotek is a digital health platform revolutionizing musculoskeletal treatment and care. Using groundbreaking motion capture technology combined with a proprietary neural network algorithm, our platform digitizes whole-body movements and produces compelling dashboards and visualizations for clinicians. No other company has combined the set ofmetrics, features and ease-of-use to support physical therapists, chiropractors, sports coaches, and other clinicians focused on movement health. | $600K / Pre-Seed / Feb 17, 2021 | |
Nuvation Bio
|
Nuvation Bio, is a privately-held biopharmaceutical company currently operating in stealth mode that is focused on the development of next generation therapies that will target the foremost unmet needs in oncology. Nuvation Bio's proprietary portfolio includes seven novel and mechanistically distinct oncology programs, each with multiple drugdevelopment candidates. Nuvation Bio was founded in 2018 by industry veteran David Hung, M.D., who previously founded and served as President and Chief Executive Officer of Medivation. Nuvation Bio has offices in New York and San Francisco. | $502M / Post-IPO Equity / Feb 11, 2021 | |
AgeRate
|
AgeRate is a developer of a biotechnology platform that helps track aging in real time. This platform utilizes predictive algorithms with multi-omic datasets to derive meaningful insights into health and longevity. The company's first product allows consumers to track their age rate and discover how they can alter their lifestyle habits toslow or reverse aging. | $250K / Pre-Seed / Sep 01, 2020 | |
Mereo Biopharma
|
Mereo is based in London and was founded in March 2015 to fund and develop novel, innovative specialist focused products from large pharmaceutical or biotechnology companies. Pharmaceutical companies face increasingly difficult choices in the allocation of internal resources to their drug development programs. With significant P&Lconstraints and rich pipelines it has become increasingly difficult for many companies to fully fund and advance development all of their drug candidates, especially beyond Phase 2. Mereo has been formed to take advantage of the global pharmaceutical industry's drive for creative ways to progress their clinical development pipelines. Mereo has acquired an initial mid-late stage portfolio of three exceptionally well characterised novel products for the treatment of diseases with considerable unmet medical need from Novartis Pharmaceuticals. Each of these programmes has a comprehensive dataset for both pre-clinical and proof-of-concept clinical studies. Additional product opportunities are under evaluation.Mereo's focus is the development of innovative medicines that have the potential to significantly transform the lives of patients suffering from rare and other specialised conditions around the world. To do this, the Company depends on the combination of its team's expertise in selecting and acquiring product opportunities, creating value in the development pipeline and structuring creative transactions. Mereo's internal expertise is complemented by a unique partnership with a leading global CRO, ICON.Mereo combines the operational discipline and efficiency of a small company with the financial resources to conduct comprehensive clinical studies. Mereo will rapidly progress each of the products through further value inflection points before partnering or divesting its products. The Company also has the option to directly commercialise products, for example in orphan disease indications. | $70M / Post-IPO Equity / Jun 04, 2020 | |
Relay Therapeutics
|
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.The company's platform detects and characterizes interactions that occur anywhere on a protein and combines computational methods with experimental approaches across the fields of structural biology,biophysics and chemistry, enabling pharmaceutical companies to solve and design therapies against complex diseases like cancer and others. | $400M / Series C / Dec 20, 2018 | |
Avidity Biosciences
|
Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissueselectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has development efforts focused on immune and other cell types. | $16M / Series B / Oct 17, 2018 | |
Atreca
|
Atreca is a biopharmaceutical that develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen. Its product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target-derived from an antibody identified using its discoveryplatform. | $125M / Series C / Sep 12, 2018 | |
Inseego
|
Inseego is a global provider of software-as-a-service and solutions for the Internet of Things. It sells its telematics solutions under the Ctrack brand, including its fleet management, asset tracking, and monitoring, stolen vehicle recovery, and usage-based insurance platforms. Inseego also sells business connectivity solutions and devicemanagement services through Novatel Wireless, Inc. and Feeney Wireless ("FW"). The company was founded in 1996 and is headquartered in San Diego, California. | $19.7M / Post-IPO Equity / Aug 07, 2018 | |
Poseida Therapeutics
|
Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our coreproprietary platforms, including our non-viral piggyBac DNA Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. | $30.5M / Series B / Apr 03, 2018 | |
G1 Therapeutics
|
G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigationaltherapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. | $47M / Series C / May 11, 2016 | |
| See all 23 investments → | |||
Co-Investors
Tavistock Life Sciences
19 deals together
EcoR1 Capital
6 deals together
Boxer Capital
3 deals together
LEAD
3 deals together
OrbiMed
3 deals together
Perceptive Advisors
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Tavistock Life Sciences invest in?
Tavistock Life Sciences invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series C and Series B stage. Most of the 23 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Tavistock Life Sciences's check size?
Tavistock Life Sciences typically joins rounds of $5M–$32M at Series B, $47M–$400M at Series C and $6M–$502M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Tavistock Life Sciences participates in.
How do I contact Tavistock Life Sciences?
Public channels for Tavistock Life Sciences include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Tavistock Life Sciences?
The team at Tavistock Life Sciences includes Christopher Fuglesang (Team Member) and Joe Lewis (Founder & Chairman). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
